Simon Rule

99PUBLICATIONS
352CO-AUTHORS
Haematological tumoursMolecular targetsApplied statisticsCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (99)

|Jul 16, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.

|Jul 02, 2026
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance.

|Jul 01, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

|Jun 04, 2026
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Apr 21, 2026
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Pageof 17

Frequent Collaborators

19 joint publications

Preetesh Jain

10 joint publications

Sairah Ahmed

9 joint publications

Jason Westin

8 joint publications

Yang Liu